pharmaceutical investing Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis
Coherus Announces Positive Phase 2b Efficacy Data on Novel Oral Therapy in Relapsing Remitting Multiple Sclerosis
Westport to Issue Q2 2025 Financial Results on August 11, 2025 and Provides an Update on the Divestment of the Light-Duty Segment
Blue Lagoon Resources Added to CSE25 Index - Recognized Among 25 Largest Companies on the Canadian Securities Exchange
SAGA Metals Mobilizes and Commences Summer Work Programs at Recently Drilled 100% Owned Radar Titanium Property in Labrador, Canada & Provides Corporate Update
RUA GOLD Closes C$13.8 Million Brokered Offering Including the Full Exercise of Over-Allotment Option
